These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of diffuse large B-cell lymphomas. Held G; Pöschel V; Pfreundschuh M Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484 [TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
6. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Collins-Burow B; Santos ES Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647 [TBL] [Abstract][Full Text] [Related]
7. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Gisselbrecht C Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460 [TBL] [Abstract][Full Text] [Related]
8. Unresolved issues in diffuse large B-cell lymphomas. Murawski N; Zwick C; Pfreundschuh M Expert Rev Anticancer Ther; 2010 Mar; 10(3):387-402. PubMed ID: 20214520 [TBL] [Abstract][Full Text] [Related]
9. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas. Held G; Schubert J; Reiser M; Pfreundschuh M; Semin Hematol; 2006 Oct; 43(4):221-9. PubMed ID: 17027656 [TBL] [Abstract][Full Text] [Related]
10. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872 [TBL] [Abstract][Full Text] [Related]
11. [Current strategies in the treatment of advanced stage mantle cell lymphoma]. Lenz G; Dreyling M; Unterhalt M; Hiddemann W Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247 [TBL] [Abstract][Full Text] [Related]
12. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Sieniawski M; Staak O; Glossmann JP; Reineke T; Scheuss H; Diehl V; Engert A; Josting A Ann Hematol; 2007 Feb; 86(2):107-15. PubMed ID: 17103169 [TBL] [Abstract][Full Text] [Related]
13. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937 [TBL] [Abstract][Full Text] [Related]
14. [Progress in therapeutic strategy for malignant lymphoma]. Ogura M Gan To Kagaku Ryoho; 2005 Mar; 32(3):309-27. PubMed ID: 15791814 [TBL] [Abstract][Full Text] [Related]
15. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma]. Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800 [TBL] [Abstract][Full Text] [Related]
16. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026 [TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560 [TBL] [Abstract][Full Text] [Related]
18. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905 [TBL] [Abstract][Full Text] [Related]
19. Rituximab: new indication. In aggressive non Hodgkin lymphoma: benefits must be confirmed. Prescrire Int; 2003 Aug; 12(66):125-6. PubMed ID: 12906019 [TBL] [Abstract][Full Text] [Related]
20. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Olivieri A; Lucesole M; Capelli D; Gini G; Montanari M; Candela M; Troiani E; Scortechini I; Poloni A; Leoni P Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]